Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 209

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 209
---
N without requiring a paternal sample or invasive procedures such as amniocentesis. Our portfolio delivers unmatched clinical insights through the screening for recessive conditions, aneuploidies, and fetal antigens using a single maternal blood draw. We believe our offering provides the most comprehensive view of fetal health available today.

| 53 |     | Hsieh, V., Sherer, D. M., Davydovych, K., Kheyman, M., & Dalloul, M. (2025). The art (and science) of Individualized Selection of Non-Invasive Prenatal Screening (NIPS). International Journal of Women S Health, 
 Volume 17, 1271–1283,                                                                                                                                                                                              |

| 54 |     | Strauss, T. S., Schneider, E., Boniferro, E., Brockhoff, E., Johnson, A., Stoffels, G., Feldman, K., Grubman, O., Cole, D., Hussain, F., Ashmead, G., Al-Ibraheemi, Z., & Brustman, L. (2023). Barriers to completion 
 of expanded carrier screening in an inner city population. Genetics in Medicine, 25(7), 100858.                                                                                                                       |

143

UNITY Fetal Risk Screen In 2019, we launched UNITY Fetal Risk Screen as the first sgNIPT that uses cfDNA to provide fetal risk assessments for recessive conditions. This breakthrough approach addresses a major gap in traditional carrier screening and enhances accessibility, speed, and accuracy for all pregnant patients. In May 2025, we expanded UNITY Fetal Risk Screen’s testing menu to include up to 14 conditions, as shown in the below figure, further enhancing its clinical impact. Available interventions for the early detection of the 14 conditions screened by UNITY Fetal Risk Screen Spinal Muscular Atrophy Cystic Fibrosis Sickle Cell Disease Beta-Thalassemia Alpha-Thalassemia Tay Sachs Disease Smith-lemi-Opitz Syndrome Fragile X Syndrome Canavan Disease Familial Dysautonomia PMM2-Congenital Disorder of Glycosylation DMD-Associated Dystrophinopathies Phenylalanine Hydroxylase Defficiency (PKU) Medium Chain Acyl-CoA Dehydrogenase Deficiency Gene or Enzyme Therapies Early detection enables access to therapies that may significantly improve outcomes Multidisciplinary Care Early detection connects families with specialists for